Insider Buying: La Jolla Pharmaceutical (LJPC) COO Acquires $33,220.00 in Stock

La Jolla Pharmaceutical (NASDAQ:LJPC) COO Jennifer Carver bought 1,000 shares of the company’s stock in a transaction dated Thursday, December 27th. The stock was bought at an average cost of $33.22 per share, with a total value of $33,220.00. Following the completion of the transaction, the chief operating officer now owns 4,500 shares in the company, valued at approximately $149,490. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Jennifer Carver also recently made the following trade(s):

  • On Wednesday, December 27th, Jennifer Carver bought 1,000 shares of La Jolla Pharmaceutical stock. The stock was bought at an average cost of $33.22 per share, with a total value of $33,220.00.

La Jolla Pharmaceutical (LJPC) opened at $33.85 on Thursday. La Jolla Pharmaceutical has a 12-month low of $16.71 and a 12-month high of $39.28. The stock has a market cap of $749.62, a PE ratio of -6.64 and a beta of 1.63.

La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.05. analysts anticipate that La Jolla Pharmaceutical will post -4.91 EPS for the current year.

LJPC has been the subject of several research analyst reports. Jefferies Group reaffirmed a “buy” rating and issued a $40.00 target price on shares of La Jolla Pharmaceutical in a research report on Tuesday, October 3rd. Chardan Capital reissued a “buy” rating and set a $90.00 price target on shares of La Jolla Pharmaceutical in a research report on Friday, December 22nd. SunTrust Banks reissued a “buy” rating and set a $65.00 price target (down from $67.00) on shares of La Jolla Pharmaceutical in a research report on Friday, December 22nd. HC Wainwright started coverage on shares of La Jolla Pharmaceutical in a research report on Thursday, December 21st. They set a “buy” rating and a $62.00 price target for the company. Finally, Zacks Investment Research raised shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $57.14.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Emory University bought a new stake in La Jolla Pharmaceutical during the 2nd quarter valued at about $1,410,000. Cowen Inc. increased its stake in La Jolla Pharmaceutical by 375.6% during the 3rd quarter. Cowen Inc. now owns 93,700 shares of the biopharmaceutical company’s stock valued at $3,259,000 after purchasing an additional 74,000 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new stake in La Jolla Pharmaceutical during the 3rd quarter valued at about $6,295,000. Vanguard Group Inc. increased its stake in La Jolla Pharmaceutical by 23.3% during the 2nd quarter. Vanguard Group Inc. now owns 816,779 shares of the biopharmaceutical company’s stock valued at $24,316,000 after purchasing an additional 154,494 shares in the last quarter. Finally, Pictet Asset Management Ltd. bought a new stake in La Jolla Pharmaceutical during the 3rd quarter valued at about $13,266,000.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/01/04/insider-buying-la-jolla-pharmaceutical-ljpc-coo-acquires-33220-00-in-stock.html.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Insider Buying and Selling by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply